Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT032 CAR-T in R/R B-NHL
NCT03994913Phase 2Completed
- Sponsor
- CARsgen Therapeutics
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of CT032 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by CARsgen Therapeutics. Started Aug 2019; status: completed.
02
Drugs
CT032
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03994913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994913.